Rebecca Elstrom
Overview
Explore the profile of Rebecca Elstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
859
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herrera A, Patel M, Burke J, Advani R, Cheson B, Sharman J, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1294-1301.
PMID: 34980599
Purpose: Targeting CD79B using antibody-drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates...
2.
Tam C, Quach H, Nicol A, Badoux X, Rose H, Prince H, et al.
Blood Adv
. 2020 Oct;
4(19):4802-4811.
PMID: 33022066
Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its...
3.
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al.
Clin Cancer Res
. 2020 May;
26(16):4216-4224.
PMID: 32461234
Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse is poor, and treatment choices...
4.
Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al.
Leukemia
. 2019 Sep;
34(2):533-542.
PMID: 31520078
Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of or who are ineligible for autologous stem cell transplant. We evaluated the efficacy and safety...
5.
Tam C, Trotman J, Opat S, Burger J, Cull G, Gottlieb D, et al.
Blood
. 2019 Jul;
134(11):851-859.
PMID: 31340982
Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation)...
6.
Pera B, Tang T, Marullo R, Yang S, Ahn H, Patel J, et al.
Clin Epigenetics
. 2016 Jul;
8:79.
PMID: 27453763
Background: Refractory and/or relapsed diffuse large B cell lymphoma (RR-DLBCL) patients are incurable with conventional chemotherapy due to the aggressiveness and the chemorefractory state of these tumors. DNA hypermethylation and...
7.
Coughlan M, Elstrom R
Cancer Imaging
. 2015 Jan;
14:34.
PMID: 25608713
Positron emission tomography (PET) using 18fluoro-2-deoxyglucose (FDG) has become a standard clinical tool for staging and response assessment in aggressive lymphomas. The use of PET scans in clinical trials is...
8.
Straus D, Hamlin P, Matasar M, Palomba M, Drullinsky P, Zelenetz A, et al.
Br J Haematol
. 2014 Oct;
168(5):663-70.
PMID: 25316653
The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established. A variation was made on rituximab (R), cyclophosphamide (C), etoposide (E), procarbazine...
9.
Panarelli N, Furman R, Wang Y, Elstrom R, Cohen J, Chadburn A
J Hematop
. 2011 Mar;
3(1):35-40.
PMID: 21373175
NK/T lymphomas have rarely been reported in HIV/AIDS patients. Here we report a case of a 37-year-old woman, with AIDS and a recent diagnosis of Kaposi sarcoma in a mesenteric...
10.
Ruan J, Martin P, Furman R, Lee S, Cheung K, Vose J, et al.
J Clin Oncol
. 2010 Dec;
29(6):690-7.
PMID: 21189393
Purpose: The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with...